Hormonal
Treatment with GLP-1 receptor agonists (e.g., semaglutide 2.4 mg, liraglutide 3.0 mg) or GLP-1/GIP co-agonists (tirzepatide) is recommended for adults with overweight or obesity at moderate or high ASCVD risk to reduce weight and cardiovascular risk factors.
If you have overweight or obesity and are at moderate or high cardiovascular risk, ask your doctor about GLP-1 medications like semaglutide or tirzepatide. These are recommended treatments that significantly reduce weight and cardiovascular risk factors, often more effectively than lifestyle changes alone.
Treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA) or GLP-1/Glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonist is RECOMMENDED for adults with overweight or obesity at MODERATE or HIGH ASCVD RISK to reduce weight and CV risk factors.
Why this rating
Based on multiple large RCTs (STEP 1, SURMOUNT-1, SCALE) with low heterogeneity.
Source
2025 Brazilian evidence-based guideline on the management of obesity and prevention of cardiovascular disease and obesity-associated complications: a position statement by five medical societies
Cynthia Melissa Valério et al. · Diabetology & Metabolic Syndrome · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →